‘NIO now requires a test before using assisted driving following fatal crash’ -Electrek Report

https://electrek.co/2021/08/24/nio-now-requires-a-test-before-using-assisted-driving-following-fatal-crash/

byBenzinga Newsdesk

August 24, 2021

1 minute read

NIO now requires a test before using assisted driving following fatal crash

Universal Forest Products Q2 EPS $2.78 Beats $1.80 Estimate, Sales $2.70B Beat $2.26B Estimate

By Benzinga Newsdesk

July 21, 4:14 PM

Universal Forest Products (NASDAQ:UFPI) reported quarterly earnings of $2.78 per share which beat the analyst consensus estimate of $1.80 by 54.44 percent. This is a 157.41 percent increase over earnings of $1.08 per

UFPI

FDA Rejects Eli Lilly’s Donanemab For Alzheimer’s Disease, Needs More Data

By Vandana Singh

January 20, 6:22 AM

The FDA issued a complete response letter for the accelerated approval submission of Eli Lilly And Co’s (NYSE:LLY) donanemab for early symptomatic…

BIIB

Susquehanna Maintains Neutral on SM Energy, Lowers Price Target to $34

By Benzinga Newsdesk

February 27, 10:26 AM

Susquehanna analyst Biju Perincheril maintains SM Energy (NYSE:SM) with a Neutral and lowers the price target from $36 to $34.

Stifel Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $56

By Benzinga Newsdesk

July 26, 8:48 AM

Stifel analyst Dae Gon Ha maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $67 to $56.

RCKT

‘NIO now requires a test before using assisted driving following fatal crash’ -Electrek Report

Related Posts

Universal Forest Products Q2 EPS $2.78 Beats $1.80 Estimate, Sales $2.70B Beat $2.26B Estimate

FDA Rejects Eli Lilly’s Donanemab For Alzheimer’s Disease, Needs More Data

Susquehanna Maintains Neutral on SM Energy, Lowers Price Target to $34

Stifel Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $56